This inventor holds 2 USPTO granted patents. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.. Active years: 2018-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2019
Title: Zhichao Xie: Innovator in Pharmaceutical Chemistry
Introduction
Zhichao Xie is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of piperidine derivatives. With a total of 2 patents, his work focuses on innovative solutions for medical applications.
Latest Patents
Zhichao Xie's latest patents include a piperidine derivative and its preparation method, along with its pharmaceutical use. This invention relates specifically to a piperidine derivative represented by a general formula, which serves as an estrogen receptor modulator. The application of this derivative is particularly relevant in the treatment of estrogen receptor-mediated diseases, such as breast cancer. The detailed description of each substituent in the general formula is provided in the patent documentation.
Career Highlights
Throughout his career, Zhichao Xie has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Zhichao Xie has collaborated with several professionals in his field, including Shanghai Yu and Fanglong Yang. These collaborations have likely enhanced his research and development efforts, leading to impactful innovations.
Conclusion
Zhichao Xie stands out as a significant figure in pharmaceutical innovation, particularly with his work on piperidine derivatives. His contributions are poised to make a difference in the treatment of critical health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile